American Heart Association consensus statement

December 08, 2003

In response to a series of reports linking popular diabetes medications to congestive heart failure, the American Heart Association and the American Diabetes Association have issued recommendations to guide physicians and patients in the use of glucose-lowering agents known as thiazolidinones (TZDs). The statement appears in today's print issue of Circulation: Journal of the American Heart Association.

The statement will also be published in the January issue of Diabetes Care.

Diabetes is a major risk factor for heart disease. TZD agents rosiglitizone maleate (Avandia) and pioglitazone hydrochloride (Actos) help doctors manage patients' glucose (blood sugar) levels and may even modify other heart disease risk factors such as high blood pressure, high cholesterol and inflammation, said Richard W. Nesto, M.D., chair of the department of cardiovascular medicine at the Lahey Clinic in Burlington, Mass., and lead author of the joint statement.

"There is now widespread use of TZDs in a broad group of patients with type 2 diabetes. At the same time there have been reports of congestive heart failure associated with their use," Nesto said.

In some people, the drugs are associated with fluid retention known as edema, especially swelling of the feet. Edema may also be a hallmark of congestive heart failure.

"It is sometimes difficult to know whether such swelling is a benign side effect of the drugs or a more ominous sign of heart failure," Nesto said. "It is this common association that concerns both cardiologists and diabetologists."

The joint writing group examined existing studies to identify patients with diabetes who are at increased risk for congestive heart failure and may not be ideal candidates for the thiazolidinedione class of drugs. "This gives us a way to manage risk," Nesto said. It also helps physicians and patients balance potential risk against "an otherwise excellent class of drugs that can improve glycemic control."

The consensus statement recommends that people with advanced heart disease or severe congestive heart failure should avoid TZDs. Also, people who don't have symptoms of congestive heart failure but whose hearts have impaired pumping ability should only use TZDs if no other means of glucose control has worked. In these extreme cases the drugs should be started at low doses.

Diabetic patients with mild to moderate congestive heart failure can also use TZDs. But the joint statement cautions that the drugs should be used with a "start low, go slow" regimen. This same low-dose, careful monitoring approach should be followed for people who don't have heart disease, but who do have one or more risk factors for congestive heart failure.

Because diabetes is a risk factor for heart disease, many patients prescribed TZDs for glucose control could also have underlying heart disease, he said.

"But at this point we don't know the real risk because we don't know either the actual number of patients with diabetes who are taking a TZD and develop congestive heart failure, compared to the total number of patients who are taking a TZD," he said. "This risk is probably quite low, but without solid data that's just guesswork."

Risk factors for congestive heart failure include heart attack, a history of heart failure, high blood pressure, enlargement of the left ventricle, heart valve disease, age older than 70, long-standing diabetes, chronic renal failure or a history of edema. Insulin use is also an important consideration since TZDs are more likely to trigger edema in persons who use insulin.

The new statement also urges patients taking TZDs to report weight gain of more than 3 kilograms (6.6 pounds), sudden onset of edema in the feet, shortness of breath or fatigue. If congestive heart failure is diagnosed after a TZD is started, use of the drug should be reconsidered. "Dosage change and temporary or permanent discontinuance are the obvious options, but no one of these is preferred for all patients," the AHA/ADA statement advises.

Co-authors are David Bell, M.D.; Robert O. Bonow, M.D.; Vivian Fonseca, M.D.; Scott M. Grundy, M.D., Ph.D.; Edward S. Horton, M.D.; Martin Le Winter, M.D.; Daniel Porte, M.D.; Clay F. Semenkovich, M.D.; Sidney Smith, M.D.; Larry Young, M.D.; and Richard Kahn, Ph.D.
-end-


American Heart Association

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.